Media
Anesiva to Present at BIO InvestorForum Conference on October 18, 2006
SOUTH SAN FRANCISCO, Calif., Oct 13, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today that James Z. Huang, the company's president, will present at the Biotechnology Industry Organization's "BIO InvestorForum 2006" on October 18, 2006 at 3:00 pm PDT in San Francisco.
To access the live webcasts or the subsequent archived recordings, log on to www.anesiva.com and go to the Investors page, and click on Events. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has three drug candidates in development for multiple pain-related indications, the most advanced of which, Zingo(TM), has completed Phase 3 clinical trials. The second product in the pipeline, 4975, has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site- specific, moderate-to-severe pain. 1207, a new local anesthetic that is undergoing preclinical development as a topical local anesthetic, is anticipated to enter the clinic in 2006. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to www.anesiva.com .
SOURCE Anesiva, Inc.
Jennifer Cook Williams, Vice President, Investor Relations or Anesiva, +1-650-624-9600, or [email protected]
http://www.anesiva.com/
Copyright (C) 2006 PR Newswire. All rights reserved
News Provided by COMTEX
